Department / Division
Pediatrics / Pediatrics-Infectious Diseases
Durham, NC 27710
Pediatric HIV infection and AIDS, evaluation of recurrent infections, evaluation of fevers of unknown origin (FUO)
Dr. Ross McKinney's research is in the antiretroviral treatment of HIV infected children, and he has additionally published articles on the natural history and pathogenesis of pediatric HIV disease. Dr. McKinney chaired Pediatric AIDS Clinical Trials Group Protocol 300, a large (600 patient) study of zidovudine, didanosine, and lamivudine in HIV infected children. He recently Co-chaired PACTG 1021 (A phase I-II study of FTC, DDI, and efavirenz), and PACTG 390/PenPact 1 (an international study of treatment strategies for therapy naive children). Dr. McKinney also cochaired PACTG 247, a study of nutritional supplementation in HIV exposed and infected infants.
As of July 2007, Dr. McKinney became the director of the Trent Center for Bioethics, Humanities, and History of Medicine in the Duke University School of Medicine. His current research involves the ethics of medical research, with a particular focus on conflict of interest and on the informed consent process.
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
McKinney, RE; Cunningham, CK. Newer treatments for HIV in children. Current Opinion in Pediatrics. 2004;16:76-79. (2004) Abstract
Benjamin, DK; Miller, WC; Benjamin, DK; Ryder, RW; Weber, DJ; Walter, E; McKinney, RE. A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. AIDS. 2003;17:2331-2336. (2003) Abstract
McKinney, RE; Johnson, GM; Stanley, K; Yong, FH; Keller, A; O'Donnell, KJ; Brouwers, P; Mitchell, WG; Yogev, R; Wara, DW; Wiznia, A; Mofenson, L; McNamara, J; Spector, SA. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. Journal of Pediatrics. 1998;133:500-508. (1998) Abstract
McKinney, RE; Wilfert, C. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group. Journal of Pediatrics. 1994;125:728-733. (1994) Abstract
McKinney, RE; Maha, MA; Connor, EM; Feinberg, J; Scott, GB; Wulfsohn, M; McIntosh, K; Borkowsky, W; Modlin, JF; Weintrub, P. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. New England Journal of Medicine. 1991;324:1018-1025. (1991) Abstract
McKinney, RE; Pizzo, PA; Scott, GB; Parks, WP; Maha, MA; Lehrman, SN; Riggs, M; Eddy, J; Lane, BA; Eppes, SC. Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group. Journal of Pediatrics. 1990;116:640-647. (1990) Abstract